Dr Lazar Remen (1907-74) was the first, in 1932, to describe the beneficial effect of prostigmine on a myasthenia gravis patient. His observation actually preceeded by two years Mary Broadfoot Walker's (1888-1974) paper, which is considered to be the landmark article on this association.
Get full access to this article
View all access options for this article.
References
1.
KeeseyJC. Contemporary opinions about Mary Walker: a shy pioneer of therapeutic neurology.Neurology1998; 51: 1433–9.
2.
JohnstonJD. The contribution of Dr Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London.Journal of the History of the Neurosciences2005; 14: 121–37.
3.
PearceJM. Mary Broadfoot Walker (1888-1974): a historic discovery in myasthenia gravis.European Neurology2005; 53: 51–3.
RemenL. Zur Pathogenese und Therapie der Myasthenia gravis pseudoparalytica.Dtsch Z Nervenheilk1932; 128: 66–78.
7.
FingerS. Minds behind the brain. A history of the pioneers and their discoveries.Oxford: Oxford University Press,2004.
8.
MillerFMJr, DoddsHH. Prostigmin treatment of myasthenia gravis.Psychiatric Quarterly1939; 13: 90–95.
9.
RemenL (MD Thesis). Uber weibliche Genitaltuberkulose mit besonderer Berucksichtigung der Strahlenbehandlung. Inaugural dissertation, medizinischen fakultat der Universitat Koln, Aus der Frauenklinik der Universitat Koln, director Prof. Dr H Futh. 1931.
RemenL. Kreatinurie und Ovarialfunktion.Ztschr F D Ges Exper Med1932; 81: 223–6.
12.
RemenL. Uber den Abban parentral zugefuhrten Kreatins bei Erwachsenen mit erloschener Geschlechtsfunktion.Z Exper Med1931; 80: 238–44.
13.
RemenL. Blutsenkungsgesschwindigkeit bei diabetes mellitus.Klin Wchnschr1931; 10: 1–5.
14.
RemenL. Erwiderung.Klin Wchnsch1932; 11: 687.
15.
SteinitzH, RemenL. Zystinuria mit doppelseitigen Nierensteinen.Medizinische Klinik1931; 49: 1–3.
16.
RemenL. Periziose anemie und Leberzirrhose.Medizinische Klinik1932; 50: 1–3.
17.
RemenL. Uber symmetrische Atrophie und deformitat des os naviculare pedis beim Erwachsenen zugleich ein Beitrag zur Frage des os supranaviculare.Rontgenpraxis1931; 21: 997–9.
18.
RemenL. Zur behandelung der myasthenia pseudoparalytica mit glykokoll.Deutsche Med Wochnschr1932; 23: 1–2.
19.
CostaA, BaroneVG. Glycocol: effects of IV injections in well and diabetic subjects.Boll d soc Ital di boil Sper1931; 6: 21–4.
20.
BufanoM. Behavior of amino-acids in blood after IV injection of glycocol in various functional tests of liver.Arch di Farmacol Sper1930; 48: 493–502.
21.
ZunzE. Glycocoll effects on coagulation.Arch Di Farmacol Sper1930; 48: 1117–32.
22.
KirschB. Glycocoll effects on tissue respiration.Biochem Ztschr1931; 238: 351–63.
23.
PascuzziR. The Edrophonium test. Seminars in neurology.Neurological Office Procedures2003; 23: 83–8.
24.
VietsHR, SchwabRS. Prostigmin in the diagnosis of myasthenia gravis.New England Journal of Medicine1935; 213: 1280–2.
25.
VietsHR. The Miracle at St. Alfege's.Medical History1965; 9: 184–5.
26.
PerloVP, PoskanzerDC, SchwabRS, VietsHR, OssermanKE, GenkinsG. Myasthenia gravis: evaluation of treatment in 1355 patients.Neurology (Minneapolis)1966; 16: 431–9.
